The Korean Journal of Internal Medicine · 2014 · 18 citations · 22 references
MedicineImmunologyPharmacotherapyAutoimmunityBone MetabolismRheumatologyBone HealthBone Metabolism DisordersBone Metabolism PharmacotherapyInflammatory ArthritisMetabolic Bone DiseaseRheumatoid ArthritisBone Enzyme MarkersBone Formation MarkersBone Resorption InhibitionBone Resorption MarkersDisease-modifying Anti-inflammatory DrugsRheumatoid Arthritis-associated Bone LossTumor Necrosis Factor Inhibitor TherapyTumor Necrosis Factor Therapy
BACKGROUND/AIMS: Our aim was to assess whether short-term treatment with soluble tumor necrosis factor (TNF) receptor affects circulating markers of bone metabolism in rheumatoid arthritis (RA) patients. METHODS: Thirty-three active RA patients, treated with oral disease-modifying antirheumatic drugs (DMARDs) and glucocorticoids for > 6 months, were administered etanercept for 12 weeks. Serum levels of bone metabolism markers were compared among patients treated with DMARDs at baseline and after etanercept treatment, normal controls and naive RA patients not previously treated with DMARDs (both age- and gender-matched). RESULTS: Bone-specific alkaline phosphatase (BSALP) and serum c-telopeptide (CTX)-1 levels were lower in RA patients treated with DMARDs than in DMARD-naive RA patients. After 12 weeks of etanercept treatment, serum CTX-1 and sclerostin levels increased. In patients whose DAS28 improved, the sclerostin level increased from 1.67 ± 2.12 pg/mL at baseline to 2.51 ± 3.03 pg/mL, which was statistically significant (p = 0.021). Increases in sclerostin levels after etanercept treatment were positively correlated with those of serum CTX-1 (r = 0.775), as were those of BSALP (r = 0.755). CONCLUSIONS: RA patients treated with DMARDs showed depressed bone metabolism compared to naive RA patients. Increases in serum CTX-1 and sclerostin levels after short-term etanercept treatment suggest reconstitution of bone metabolism homeostasis.
22
Revised Criteria for the Classification of Rheumatoid Arthritis
Frank C. Arnett · Orthopaedic Nursing · 1990 · 7.7K citations
Anke M. van Gestel, M.L.L. Prevoo, Martin A. van't Hof et al. · Arthritis & Rheumatism · 1996 · 1.6K citations
Sclerostin Binds to LRP5/6 and Antagonizes Canonical Wnt Signaling
Xiaofeng Li, Heeseog Kang, Wenzhong Liu et al. · Journal of Biological Chemistry · 2005 · 1.4K citations · Full text
Dickkopf-1 is a master regulator of joint remodeling
Danielle Diarra, Marina Stolina, Karin Polzer et al. · Nature Medicine · 2007 · 1.3K citations